JP6675119B2 - 選択的な染色体タンパク質のアシル化を行うための人工触媒システム - Google Patents
選択的な染色体タンパク質のアシル化を行うための人工触媒システム Download PDFInfo
- Publication number
- JP6675119B2 JP6675119B2 JP2015169448A JP2015169448A JP6675119B2 JP 6675119 B2 JP6675119 B2 JP 6675119B2 JP 2015169448 A JP2015169448 A JP 2015169448A JP 2015169448 A JP2015169448 A JP 2015169448A JP 6675119 B2 JP6675119 B2 JP 6675119B2
- Authority
- JP
- Japan
- Prior art keywords
- acylation
- catalyst
- target
- coa
- dsh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000010933 acylation Effects 0.000 title description 76
- 239000003054 catalyst Substances 0.000 title description 76
- 230000002759 chromosomal effect Effects 0.000 title description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 239000003118 drug derivative Substances 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 description 72
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 47
- 230000027455 binding Effects 0.000 description 38
- 230000021736 acetylation Effects 0.000 description 31
- 238000006640 acetylation reaction Methods 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 23
- 108010033040 Histones Proteins 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 102000006947 Histones Human genes 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 108010047956 Nucleosomes Proteins 0.000 description 13
- 210000001623 nucleosome Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 102000003893 Histone acetyltransferases Human genes 0.000 description 5
- 108090000246 Histone acetyltransferases Proteins 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 230000017538 malonylation Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WOSPSCVWXYVYJD-UHFFFAOYSA-N [4-(methylamino)pyridin-2-yl]methanol Chemical compound CNC1=CC=NC(CO)=C1 WOSPSCVWXYVYJD-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000006242 butyrylation Effects 0.000 description 4
- 238000010514 butyrylation reaction Methods 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- GWKFSPITSLFUER-UHFFFAOYSA-N 3-[methyl-[2-(tritylsulfanylmethyl)pyridin-4-yl]amino]propanoic acid Chemical compound CN(CCC(=O)O)C1=CC(=NC=C1)CSC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 GWKFSPITSLFUER-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101710103773 Histone H2B Proteins 0.000 description 3
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 239000012345 acetylating agent Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000006195 histone acetylation Effects 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- HWZKQIRJZPOEQF-UHFFFAOYSA-N n-acetyl-n-methoxyacetamide Chemical compound CON(C(C)=O)C(C)=O HWZKQIRJZPOEQF-UHFFFAOYSA-N 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 150000007970 thio esters Chemical group 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- WLDPWZQYAVZTTP-UHFFFAOYSA-N 1-methyl-imidazole-2-carboxylic acid Chemical compound CN1C=CN=C1C(O)=O WLDPWZQYAVZTTP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MUEOQEUSJMFYHV-UHFFFAOYSA-N 4-amino-1-methylpyrrole-2-carboxylic acid Chemical compound CN1C=C(N)C=C1C(O)=O MUEOQEUSJMFYHV-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(2)(1)に記載の化合物とアシルCoA若しくはその誘導体との組み合わせを含む、染色体タンパク質をアシル化するための薬剤。
本発明は、標的アシル化領域結合性触媒、具体的には、下記の構造を有する化合物を提供する。
本発明の標的アシル化領域結合性触媒は、本発明の人工触媒システムの一つの構成要素であり、アシルCoA若しくはその誘導体との組み合わせで、高い選択性でタンパク質のアシル化を行うことができる。
本実施例において、標的アシル化領域結合性触媒とアシルCoA若しくはその誘導体との組み合わせにより、染色体タンパク質をアシル化できることが見出された。従って、本発明は、上記標的アシル化領域結合性触媒とアシルCoA若しくはその誘導体との組み合わせを含む、染色体タンパク質をアシル化するための薬剤を提供する。また、本発明は、当該組み合わせを用いる、染色体タンパク質をアシル化する方法を提供する。
1.細胞分画
約106個の細胞をトリプシン処理により培養ディッシュより剥がし、PBSで洗浄後、細胞ペレットを冷却したcell lysis buffer [50mM Tris(pH7.5), 300mM NaCl, 0.3% Triton X-100, protease inhibitor cocktail および1mM PMSF]で懸濁し、30分氷上に静置した。遠心(4℃, 1500rpmで2分間)後、上清を細胞質画分として回収した。
タンパク質を4-20% SDS-PAGEゲルで分離し、PVDF膜に転写した後、TBSTに懸濁した5%スキムミルクによりブロッキングを行い、PVDF膜に1次抗体を反応させた。用いた1次抗体は以下の通りである。
緩衝液(50mM HEPES, 150mM NaCl, 0.01% Triton, pH7.5)に細胞質画分(20%)とアセチル基供与体(1mM)を加え、室温で10時間反応させた後、抗アセチルリジン抗体を用いてウエスタンブロッティングを行った。
再構成ヌクレオソーム(33μg/mL 601 DNA)および細胞質画分(15%)を含む緩衝液(20mM Tris-HCl, pH7.5)に、Ligand-DSH(2〜5μM), アシルCoA(1mM), TCEP(100μM)を加え、室温で5時間反応させた後、ウエスタンブロッティングを行った。
(1)サンプル調製
Ligand-DSH(2μM), アセチルCoA(1mM), TCEP(100μM)を緩衝液(20mM Tris-HCl, pH7.5)中で1時間反応させた後、再構成ヌクレオソーム(33μg/mL 601 DNA)を加えてさらに5時間反応させた(最終液量150μL)。冷却したトリクロロ酢酸(30uL)を加えて、氷上で30分間静置し、遠心後(4℃, 15000rpmで5分間)上清を捨てた。さらに遠心(4℃, 15000rpmで1分間)して再度上清を捨てた。冷却したアセトン(450μL)を加え、遠心後(4℃, 15000rpmで5分間)上清を捨て、さらに遠心(4℃, 15000rpmで1分間)して再度上清を捨てた。これをもう一度繰り返した。遠心エバポレーターで10分間乾燥した後、MilliQ(89μL), 10X DNase buffer(10μL), DNase I(1μL, #2270A, Takara)を加えて、37℃で30分間反応させた。1M硫酸(25μL)を加えて氷上で1時間静置した後、遠心(4℃, 15000rpmで5分間)して上清を回収した。再び遠心(4℃, 15000rpmで1分間)して上清を回収し、先の上清と合わせた。そこに冷却したアセトン(500μL)を加えてよく撹拌したのち、-30℃で一晩静置した。遠心後(4℃, 15000rpmで5分間)上清を捨て、さらに遠心(4℃, 15000rpmで1分間)して再度上清を捨てた。遠心エバポレーターで10分間乾燥した後、重炭酸アンモニウム水溶液(0.1M, 20μL)を加え、そこに直前に調製したプロピオン酸無水物とメタノールの混合物(1:3, 20μL)を加え、さらにアンモニア水(15μL)を加えて室温で30分間静置した。遠心エバポレーターで75分間乾燥した後、消化酵素で処理した。
AB Sciex Triple TOF 4600
Eksigent ekspertTM MicroLC 200
カラム: 3C18-CL-120(0.3mm ID x 150mm)
直線勾配 2%-35%アセトニトリル/0.1%ギ酸, 25分, 5μL/分
サンプル量:5μL
ESI-Q-TOF MS, positive-ion mode.
(3)収率の決定方法
収率の決定方法の概要を図4に示した。
プリカーサーイオンを指定し、それぞれのプリカーサーイオンに対し最も強度の高い2つから4つのMS/MSフラグメントイオンを選択した。指定したプリカーサーイオンおよびMS/MSフラグメントイオンでイオン抽出(±0.5Da)し、以下の式に従って収率を算出した。それを選択したMS/MSフラグメントの全てについて行い、それらの平均を最終収率として決定した。
(ここで、Aはアセチル化ペプチドのピークエリアを示し、Pはプロピオニル化ペプチドのピークエリアを示す)
ひとつのペプチド断片に3つのリジンを含む場合、中央のリジンの収率は
[端2つのリジンどちらかにアセチル化が進行した収率-最端のリジンの収率]
として計算した。
Information Dependent Acquisition Modeで測定を行うことで得られたクロマトグラムに対し、プリカーサーイオンを指定してイオン抽出(±0.5Da)したピークエリアから以下の式に従って収率を決定した。
(ここで、Aはアセチル化ペプチドのピークエリアを示し、Pはプロピオニル化ペプチドのピークエリアを示す)
Method C
Information Dependent Acquisition Modeで測定を行うことで得られたクロマトグラムにおいて、プロピオニル化ペプチド断片は観測されるが、アセチル化ペプチド断片は観測されなかった。このため、サンプルを希釈することでプロピオニル化ペプチド断片の検出限界を算出し、アセチル化収率はその検出限界以下であるとして見積もった。
化合物3(2.30g, 16.0mmol)を12Mメチルアミン水溶液(26.7ml)に溶解し、封管中、120度で18時間加熱した。溶媒を減圧留去したのち、残渣を塩化メチレン/メタノール溶液(4/1)に溶解し、炭酸カリウム(5g)を加えて4時間撹拌した。炭酸カリウムを濾過により除き、ろ液を濃縮することで化合物4(2.01g, 14.5mmol, 88%収率)を得た。
Methyl 3-((2-(hydroxymethyl)pyridin-4-yl)(methyl)amino)propanoate (5):
化合物4(1.38g, 10.0mmol)をアクリル酸メチル(22.5ml)に溶解し、80度で18時間加熱した。溶媒を減圧留去したのち、シリカゲルカラムクロマトグラフィー(酢酸エチル/メタノール=1/0〜0/1)で精製し、化合物5(1.39g, 6.20mmol, 62%収率)を得た。
Methyl 3-((2-(chloromethyl)pyridin-4-yl)(methyl)amino)propanoate (6):
化合物5(640mg, 2.85mmol)を塩化メチレン(14.0ml)に溶解し、塩化チオニル(0.311ml, 4.28mmol)をゆっくりと滴下した。室温で10時間撹拌した後、炭酸カリウム水溶液を注意深く加え、水層を塩化メチレンで抽出、有機層を濃縮し、残渣をシリカゲルクロマトグラフィー(酢酸エチル/メタノール=1/0〜0/1)で精製し、化合物6(529mg, 2.18mmol, 76%収率)を得た。
Methyl 3-(methyl(2-((tritylthio)methyl)pyridin-4-yl)amino)propanoate (7):
化合物6(922mg, 3.80mmol)を塩化メチレン(19.0ml)に溶解し、TrtSH(1.58g, 5.72mmol)およびDBU(0.852ml, 5.70mmol)を加え、室温で10時間撹拌した。炭酸カリウム水溶液を注意深く加え、水層を塩化メチレンで抽出、有機層を濃縮し、残渣をシリカゲルクロマトグラフィー(酢酸エチル/ヘキサン=1/1〜酢酸エチル/メタノール=20/1)で精製し、化合物7(1.53g, 3.17mmol, 83%収率)を得た。
3-(Methyl(2-((tritylthio)methyl)pyridin-4-yl)amino)propanoic acid (8):
化合物7(1.45g, 3.00mmol)をメタノール(15ml)に溶解し、2M水酸化ナトリウム水溶液(7.50ml, 15.0mmol)を加えて、室温で3時間撹拌した。1M塩酸で中和した後、溶媒を留去し、シリカゲルクロマトグラフィー(酢酸エチル/メタノール=4/1〜1/2)で精製し、化合物8(1.39g, 2.97mmol, 99%収率)を得た。
HATU, iPr2NEtを縮合剤、1-Methyl-1H-imidazole-2-carboxylic acid, 4-Amino-1-methyl-1H-pyrrole-2-carboxylic acid, 4-[(9-Fluorenylmethoxycarbonyl)amino]butanoic acidをビルディングブロックとして用いて、通常のFmoc-ペプチド固相合成法に従い2-Chlorotrityl chloride resin(100mg, 1.3mmol/g, 0.133mmol)上にPIP鎖を伸長した。TFA/TIPS/H2O(95/2.5/2.5)で樹脂からの切り出しを行い、HPLC(10% アセトニトリル/0.1% TFA水溶液→直線勾配10-100% 40分, flow: 10ml/分, 230nm, YMC-Pack ODS-AM: 20mm ID x 250mm)で精製しPIP-amine(9, 31.4mg, 0.0204mmol, 15%収率)を得た。
PIP-DSTrt (10):
PIP-amine(15.4mg, 0.0100mmol)をDMF(0.18ml)に溶解し、8(23.4mg, 0.0500mmol), HATU(19.0mg, 0.0500mmol), iPr2NEt(0.0200ml, 0.115mmol)を加えて室温で9時間撹拌した。反応液を濃縮後、HPLC(10% アセトニトリル/0.1% TFA水溶液→直線勾配10-100% 40分, flow: 10ml/分, 230nm, YMC-Pack ODS-AM: 20mm ID x 250mm)で精製しPIP-DSTrt(10, 11.7mg, 0.00587mmol, 59%収率)を得た。
PIP-DSH (1):
PIP-DSTrt(11.7mg, 0.00580mmol)にTIPS(20μl), MilliQ water(20μl)およびTFA(0.160ml)を加え、室温で30分撹拌した。反応液を濃縮後、HPLC(10% アセトニトリル/0.1% TFA水溶液→直線勾配 10-100% 40min, flow: 10ml/min, 230nm, YMC-Pack ODS-AM: 20mm ID x 250mm)で精製しPIP-DSH(1, 6.85mg, 0.00393mmol, 67%収率)を得た。
DIC, HOBtを縮合剤として用いて、通常のFmoc-ペプチド固相合成法に従いRink-Amide-AM resin(75.3mg, 0.73mmol/g, 0.055mmol)上にH-GMRLRSGRSTG-を合成した。HATU, iPr2NEtを用いてN末端に化合物8を縮合させることで、樹脂状に保護LANA-DSHを合成した。TFA/TIPS/H2O(95/2.5/2.5)で脱保護および切り出しを行い、HPLC(直線勾配; 0-75% アセトニトリル/0.1% TFA水溶液, flow: 7ml/分, 30分, 254nm, YMC-Pack ODS-AM: 20mm ID x 250mm)で精製しLANA-DSH(2, 10.5mg, 0.00570mmol, 10%収率)を得た。
[B.結果]
まず用いるアセチル化剤の反応性について検討した(図1)。数種類のアセチル化剤(図1A)について、生細胞より取得した細胞質画分と混合し、アセチル化リジン抗体を用いたウエスタンブロットにより検出した。その結果、EG5-PTAやNMDは多くのタンパク質を非選択的にアセチル化した一方、生体が用いているアセチル基供与体であるアセチルCoAやその類縁体であるTEG-Acはそのような非選択的なアセチル化を引き起こさないことが判明した(図1B)。
Claims (2)
- 下記構造を有する化合物。
- 請求項1に記載の化合物とアシルCoA若しくはその誘導体との組み合わせを含む、タンパク質をアシル化するための薬剤であって、アシルCoAの誘導体が下記構造を有する化合物である薬剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015169448A JP6675119B2 (ja) | 2015-08-28 | 2015-08-28 | 選択的な染色体タンパク質のアシル化を行うための人工触媒システム |
US15/755,938 US11021461B2 (en) | 2015-08-28 | 2016-08-29 | Artificial catalyst system for selective acylation of chromosome protein |
PCT/JP2016/075183 WO2017038760A1 (ja) | 2015-08-28 | 2016-08-29 | 選択的な染色体タンパク質のアシル化を行うための人工触媒システム |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015169448A JP6675119B2 (ja) | 2015-08-28 | 2015-08-28 | 選択的な染色体タンパク質のアシル化を行うための人工触媒システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017043584A JP2017043584A (ja) | 2017-03-02 |
JP6675119B2 true JP6675119B2 (ja) | 2020-04-01 |
Family
ID=58187477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015169448A Expired - Fee Related JP6675119B2 (ja) | 2015-08-28 | 2015-08-28 | 選択的な染色体タンパク質のアシル化を行うための人工触媒システム |
Country Status (3)
Country | Link |
---|---|
US (1) | US11021461B2 (ja) |
JP (1) | JP6675119B2 (ja) |
WO (1) | WO2017038760A1 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010001933A1 (ja) * | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
US8986953B2 (en) * | 2011-01-20 | 2015-03-24 | University Of Rochester | Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation |
EP3156411B1 (en) * | 2014-06-04 | 2021-03-03 | The University of Tokyo | Artificial catalyst system capable of substituting for in vivo acylation function |
US11097009B2 (en) * | 2015-02-12 | 2021-08-24 | Kyoto University | CTB-PI polyamide conjugate for activating expression of specific gene |
-
2015
- 2015-08-28 JP JP2015169448A patent/JP6675119B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-29 US US15/755,938 patent/US11021461B2/en active Active
- 2016-08-29 WO PCT/JP2016/075183 patent/WO2017038760A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2017038760A1 (ja) | 2017-03-09 |
US20190047985A1 (en) | 2019-02-14 |
JP2017043584A (ja) | 2017-03-02 |
US11021461B2 (en) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mijanović et al. | Cathepsin B: A sellsword of cancer progression | |
EP3609889B1 (en) | Small molecules | |
JP2020203934A (ja) | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 | |
US20190375786A1 (en) | Stable peptides and methods of use thereof | |
US20090155270A1 (en) | Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza | |
US20240165245A1 (en) | Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same | |
US20110270151A1 (en) | Image-guided energy deposition for targeted drug delivery | |
WO2013142229A1 (en) | Designing novel peptides for inducing fibronectin matrix assembly | |
WO2016119067A1 (en) | Peptides derived from human pcsk9 catalytic domain and uses there of for promoting ldl-r activity | |
WO2013170257A1 (en) | Treating muc1-expressing cancers with helicase inhibitors | |
TW202227074A (zh) | Sars cov-2抑制劑及其用途 | |
US20060188476A1 (en) | Interleukin 20 (IL-20) and its use in neovascularisation | |
Hayashi et al. | Revisiting the potential of South American rattlesnake Crotalus durissus terrificus toxins as therapeutic, theranostic and/or biotechnological agents | |
US20200009221A1 (en) | Methods for inhibiting necrosis | |
JP4744443B2 (ja) | 毒素中和性ペプチドのスクリーニング方法とstx2阻害性ペプチド並びにベロ毒素中和剤 | |
US20160129078A1 (en) | Rhomboid Proteins and Uses Thereof | |
JP6675119B2 (ja) | 選択的な染色体タンパク質のアシル化を行うための人工触媒システム | |
Chowdary et al. | A short hydrophobic peptide conjugated 3, 5-disubstituted pyrazoles as antibacterial agents with DNA gyrase inhibition | |
US20150038531A1 (en) | Use of a novel aminopyridine derivative to prevent or treat cancer | |
WO2021132661A1 (ja) | ライブラリーの製造方法、環状ペプチド、FXIIa結合剤、及びIFNGR1結合剤 | |
WO2018165655A1 (en) | Antimicrobial peptides and methods of making and using same | |
JP7069126B2 (ja) | 化学療法誘発性末梢性ニューロパシーおよび難聴を処置または予防するためのbcl-wポリペプチドおよび模倣物 | |
JP6736462B2 (ja) | 生体内のアシル化機能と置き換えられる人工触媒システム | |
JP2009057318A (ja) | S−ニトロソ基含有アルブミン及びその製造方法ならびに抗がん剤 | |
TW200524576A (en) | Chemical compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190815 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200303 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6675119 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |